{"id":390543,"date":"2018-11-22T00:00:00","date_gmt":"2018-11-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0004-2018-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-03-31T10:47:42","modified_gmt":"2026-03-31T10:47:42","slug":"dlsfim0004-2018-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0004-2018-biopharma-crohns-disease-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Crohn&#8217;s Disease | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>The Crohn\u2019s disease(<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>) therapy market will continue to evolve over the next decade. The well-established\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 inhibitors (e.g., Janssen\/Merck\u2019s Remicade, AbbVie\/Eisai\u2019s Humira) helped transform the treatment landscape, especially for patients with moderate to severe disease, despite these agent\u2019s limitations in efficacy (e.g., patients lose response over time) and safety risks. Takeda\u2019s Entyvio, a cell adhesion molecule (<abbr data-original-title=\"cell adhesion molecule\" title=\"\">CAM<\/abbr>) inhibitor, and the introduction of the first-in-class interleukin (<abbr data-original-title=\"interleukin\" title=\"\">IL<\/abbr>)-12\/23 inhibitor, Janssen\u2019s Stelara, have expanded physicians\u2019 treatment armamentarium, especially for patients refractory to\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-\u03b1 inhibitors. Emerging therapies, which offer more-convenient formulations and\/or havenovel mechanisms of action (e.g., Galapagos\/Gilead\u2019s filgotinib, TiGenix\/Takeda\u2019s Alofisel, AbbVie\u2019s risankizumab), together with the increasing availability of biosimilar agents, will only intensify the competition.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are key opinion leaders\u2019 (<abbr data-original-title=\"key opinion leader\" title=\"\">KOL<\/abbr>s\u2019) insights on current treatment options (e.g., Remicade, Humira)? What is their perception of biosimilar agents? What factors drive their treatment decisions?<\/li>\n<li>How have\/will the newer, non-<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>\u00a0biologics (e.g., Janssen\u2019s Stelara, Takeda\u2019s Entyvio, Roche\u2019s etrolizumab) affect the\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>\u00a0treatment algorithm?<\/li>\n<li>What do\u00a0<abbr data-original-title=\"key opinion leader\" title=\"\">KOL<\/abbr>s think about emerging oral therapies (e.g., Galapagos\/Gilead\u2019s filgotinib, AbbVie\u2019s upadacitinib)? What impact will stem-cell therapy (i.e., TiGenix\/Takeda\u2019s Alofisel) have on the\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>\u00a0market?<\/li>\n<li>How will the market evolve over the next ten years? What are\u00a0<abbr data-original-title=\"key opinion leader\" title=\"\">KOL<\/abbr>s\u2019 insights on current treatment options for\u00a0<abbr data-original-title=\"Crohn's disease\" title=\"\">CD<\/abbr>\u00a0(e.g., Remicade, Humira, Inflectra\/Remsima)? What factors drive their treatment decisions?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390543","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390543\/revisions"}],"predecessor-version":[{"id":576688,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390543\/revisions\/576688"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}